BiotechTV - News

Renée Aguiar-Lucander describes the kidney transplant population that the therapy currently has conditional approval with the EMA for, and how Hansa it trying to expand on it. Plus, development work in Guillain-Barré syndrome and gene therapy.

He describes how sentiment and the M&A environment have been improving, as well as some areas of the financing market. However, he cautions that it is very difficult to get early-stage development funded and that companies need to be creative to get phase 1 studies done.

He describes why he likes the strong and quick elements of alpha-particles, and how Perspective's have been designed to have a short half-life. Plus, background on programs targeting MC1R, SSTR2, and FAP-α.

He describes why he believes NK cells are better suited thank T-cells for autoimmune, and updates us on the company's clinical programs. Nkarta will share a data on everything before the end of the year.

CEO Larry Edwards describes the unmet need in the immunocompromised space, and highlights Aicuris' commercial CMV product (PREVYMIS), partnered with Merck/MSD, and R&D products targeting HSV and BKV.

She describes the unmet need for a new therapy in this setting, and compares and contrasts ZUSDURI to going through multiple transurethral resection of bladder tumor (TURBT) surgeries. Plus, the potential addressable market, and what she believes the approval means for UroGen as a company.

He describes the successful transplant of Tim Andrews, who threw out the first pitch at a Red Socks game last week, and discusses what is next for this program. Plus, the status of liver and heart programs.

He explains how M&A and fundraising have been improving, and he describes what types of companies have been most appealing to investors. Plus, his take on the potential most favored nation policy, companies with negative enterprise values, and China competition.

He discusses the company's gene therapy approach to retinitis pigmentosa, Stargardt disease (which just had a pivotal cleared by FDA today), and geographic atrophy.

He goes over the results, and compares and contrasts the therapy's profile to the primary competitor that is currently on the market, Carvykti. Plus learnings from year two of a physician survey, and his current take on CAR-T for autoimmune and CD123 for AML.